A review of co‐morbid tobacco and cannabis use disorders: Possible mechanisms to explain high rates of co‐use

American Journal on Addictions - Tập 24 Số 2 - Trang 105-116 - 2015
Rachel A. Rabin1,2, Tony P. George3,1,2
1Institute of Medical Science (IMS), Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
2Schizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada
3Division of Brain and Therapeutics, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada

Tóm tắt

BackgroundTobacco and cannabis are among the most commonly used psychoactive substances worldwide, and are often used in combination. Evidence suggests that tobacco use contributes to an increased likelihood of becoming cannabis dependent and similarly cannabis use promotes transition to more intensive tobacco use. Further, tobacco use threatens cannabis cessation attempts leading to increased and accelerated relapse rates among cigarette smokers. Given that treatment outcomes are far from satisfactory among individuals engaged in both tobacco and cannabis use highlights the need for further exploration of this highly prevalent co‐morbidity.ObjectiveTherefore, this review will elucidate putative neurobiological mechanisms responsible for facilitating the link between co‐morbid tobacco and cannabis use.MethodWe performed an extensive literature search identifying published studies that examined co‐morbid tobacco and cannabis use.ResultsEvidence of both synergistic and compensatory effects of co‐morbid tobacco and cannabis use have been identified. Following, co‐morbid use of these substances will be discussed within the context of two popular theories of addiction: the addiction vulnerability hypothesis and the gateway hypothesis. Lastly, common route of administration is proposed as a facilitator for co‐morbid use.Conclusions & Scientific SignificanceWhile, only a paucity of treatment studies addressing co‐morbid tobacco and cannabis use have been conducted, emerging evidence suggests that simultaneously quitting both tobacco and cannabis may yield benefits at both the psychological and neurobiological level. More research is needed to confirm this intervention strategy and future studies should consider employing prospective systematic designs. (Am J Addict 2015;24:105–116)

Từ khóa


Tài liệu tham khảo

UNODC.World Drug Report 2012. New York2012.

10.1016/S0306-4603(99)00013-1

10.1111/j.1360-0443.2004.00531.x

10.1002/hup.766

10.1046/j.1360-0443.2002.00162.x

10.1111/j.1360-0443.2012.03837.x

10.1192/bjp.182.4.330

Office of Applied Studies. Results from the 2007 National Survey on Drug Use and Health: Detailed tables. Rockville MD: Substance Abuse and Mental Health Services Administration; 2008.

10.1136/tc.11.3.228

10.1016/j.drugalcdep.2004.11.014

10.1176/appi.ajp.161.11.1967

10.1001/archpsyc.1986.01800030107013

Fiore MC Bailey WC Cohen SJ Dorfman SF Goldstein MG Gritz ER. Treating Tobacco Use and Dependence. Rockville MD 2000.

10.1016/S0740-5472(03)00083-7

10.1016/j.drugalcdep.2008.01.011

10.1016/j.drugalcdep.2008.08.007

10.1016/j.biopsych.2012.07.028

10.1111/j.1360-0443.2008.02354.x

10.1016/j.addbeh.2008.05.008

10.1016/S0376-8716(02)00066-2

WHO;. Tobacco Free Initiative. 2012.

10.1016/S0140-6736(03)14338-3

10.1111/resp.12308

10.1001/archinte.166.13.1359

10.1016/S0379-0738(01)00609-0

Budney AJ, 2008, Health consequences of marijuana use, 171

10.15288/jsad.2007.68.886

10.1111/j.1360-0443.2012.03843.x

10.1016/0899-3289(92)90039-Z

10.1093/her/cyp027

Golub AL. The Cultural/Subcultural Contexts of Marijuana Use at the Turn of the Twenty‐First Century. Haworth Press; 2006.

10.1016/j.drugalcdep.2010.08.008

10.1542/peds.109.2.284

10.1016/j.drugpo.2006.01.004

10.1111/1469-7610.00424

10.1080/10550880903435996

10.1016/j.drugalcdep.2008.10.019

10.1016/j.neubiorev.2009.07.013

10.1038/383713a0

10.1016/S0166-2236(96)10073-4

10.1038/npp.2009.110

10.1002/neu.10148

Benowitz NL, 1982, Interindividual variability in the metabolism and cardiovascular effects of nicotine in man, J Pharmacol Exp Ther, 221, 368

Compton DR, 1992, Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents, J Pharmacol Exp Ther, 260, 201

10.1038/sj.bjp.0704327

10.1152/physrev.00019.2008

10.1046/j.0953-816x.2001.01612.x

10.1016/0014-2999(90)94136-L

10.1038/npp.2008.138

10.1016/j.pbb.2005.01.032

10.1016/S0301-0082(98)00087-2

10.1073/pnas.92.26.12304

10.1016/S0006-8993(02)03055-X

10.1016/S0014-2999(01)00723-3

10.1097/00008877-200209000-00018

10.1016/j.neuropharm.2007.10.011

10.1111/j.1369-1600.2009.00204.x

10.1007/s00213-005-0015-6

10.1016/S0028-3908(02)00118-1

10.1038/sj.bjp.0705931

10.1080/09540260902782786

10.1038/sj.bjp.0704479

10.1124/jpet.106.116830

10.1300/J069v22n03_05

10.1016/j.drugalcdep.2005.01.008

10.1016/j.drugalcdep.2008.06.017

10.1016/j.drugalcdep.2009.01.023

10.1111/j.1460-9568.2004.03714.x

10.1007/s00213-005-0251-9

10.1016/j.drugalcdep.2007.06.010

10.1046/j.1360-0443.1999.9433273.x

10.1016/j.addbeh.2008.11.013

10.1016/j.drugalcdep.2010.04.010

10.1016/j.coph.2004.08.011

10.1016/j.neuron.2004.09.016

10.1176/appi.ajp.162.8.1403

10.1007/s00213-010-1848-1

10.1038/sj.npp.1300496

10.1017/S0033291709005522

10.1016/j.bbr.2008.04.004

10.1016/j.biopsych.2006.02.014

10.1037/1064-1297.2.3.244

10.1073/pnas.191352698

10.1097/YPG.0b013e3283208026

10.1038/tp.2012.146

10.1002/gcc.22011

10.1111/ahg.12046

10.1016/j.drugalcdep.2009.11.016

10.1002/ajmg.b.30881

10.1001/archpsyc.65.7.816

10.1186/1471-2156-8-46

10.1017/S0954579499002369

10.1007/PL00005483

10.1176/appi.ajp.159.10.1642

10.1176/appi.ajp.160.6.1041

10.1007/s10519-010-9417-2

10.1037/0033-295X.112.4.862

10.1080/13803395.2012.703642

10.1016/j.ntt.2006.10.012

10.1016/j.jadohealth.2005.11.027

10.1016/S1054-139X(00)00202-0

10.1176/ajp.2006.163.12.2134

10.1111/j.1360-0443.2005.01220.x

10.1017/CBO9780511499777

10.1080/00952990802326280

10.1038/npp.2013.16

10.1126/scitranslmed.3003062

Meng Y, 1997, Inhalation studies with drugs of abuse, NIDA Res Monogr, 173, 201

10.1016/S0140-6736(06)68770-9

10.1016/j.jadohealth.2010.05.008

10.1037/0021-843X.106.1.104

10.1016/S0899-3289(01)00093-1

10.1016/j.jsat.2008.09.006

10.1081/JA-200048461

10.1136/bmj.309.6958.842

10.1080/10550490600754341

10.1177/026988119801200103

10.1176/appi.ajp.159.6.954

10.1037/0021-843X.115.1.166

10.1016/j.drugalcdep.2011.06.004

10.1037/0022-006X.72.6.1144

George TP. Nicotine and Tobacco. Vol 24th Edition New York 2011.

10.1016/j.drugalcdep.2010.12.010

Schuster CR, 1975, Drugs as reinforcers in monkey and man, Pharmacol Rev, 27, 551

10.1007/s002130050022

10.1080/10550490802408936

10.1007/s002130000657

Penetar DM, 2012, Bupropion reduces some of the symptoms of marihuana withdrawal in chronic marihuana users: A pilot study, Subst Abuse, 6, 63

10.1111/j.1521-0391.2012.12007.x

10.15288/jsa.2004.65.681

10.1016/j.cpr.2011.12.002

10.1186/1747-597X-8-33

10.1159/000321256

10.1016/j.cpr.2009.08.009

10.1111/j.1360-0443.2008.02448.x

10.4088/JCP.v64n0815

10.1056/NEJMsa0806819

10.1901/jaba.2008.41-617

10.1016/j.drugalcdep.2009.07.009

10.1016/j.addbeh.2006.08.009

Thông tin
Thông tin xuất bản

American Journal on Addictions

Tập 24 Số 2

105-116

Thông tin tác giả